Section
Deals
M&A, licensing, and major transactions shaping the industry
DealsPharmaceutical Technology ↗
Chiesi will assume ownership of Ekterly, an on-demand pill approved for hereditary angioedema.…
DealsFiercePharma ↗
As Ekterly nears the one-year anniversary of its approval, Chiesi Group is making moves to acquire the rare di…
DealsFierceBiotech ↗
Eli Lilly’s latest attempt to strengthen its genetic medicine offering has seen the pharma team up with Proflu…
DealsBioPharma Dive ↗
A Jefferies analyst argued the deal — Teva’s largest in a decade — “makes se…
DealsBriefing
Chiesi has announced a $1.9B acquisition of KalVista Pharmaceuticals, continuing 2026’s brisk deal pace among …
DealsBriefing
Lilly’s $2.3 billion move for Ajax Therapeutics centers on a Type II JAK2 inhibitor it helped incubate, aiming…
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.